NoNO-42 Archives - NeuroNews International

NoNO announces first patient dosed with NoNO-42 in Phase 1 study

22 November 2022

NoNO Inc has announced the dosing of the first participant in its Phase 1 clinical trial evaluating NoNO-42—a next-generation neuroprotective drug developed in the...

Write to us
Editor: Jamie Bell [email protected]
Advertising: Michael Broughton [email protected]

United Kingdom:

BIBA Medical, Europe
526 Fulham Road, Fulham, London, SW6 5NR
TEL: +44 (0)20 7736 8788
Email: [email protected]

United States:

BIBA Medical, North America
155 North Wacker Drive, Suite 4250, Chicago, IL 60606
TEL: +1 949 723 9309
Email: [email protected]

Terms and Conditions | Privacy Policy

Tag: NoNO-42

NoNO announces first patient dosed with NoNO-42 in Phase 1 study